New Hope for Treating Hepatitis C: Telaprevir, Saint Louis University School of Medicine Study

Newswise — A study co-authored by a Saint Louis University researcher found telaprevir, a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients than standard treatment alone. The findings were published in the April 8 issue of the New England Journal of Medicine.

Back to news